ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR CYP-MEDIATED DRUG-DRUG INTERACTIONS

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016


ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR CYP-MEDIATED DRUG-DRUG INTERACTIONS

	Reported by Jules Levin EASL 2016 April 14-17 Barcelona Matthew P. Kosloski, Sandeep Dutta, David Pugatch, Hong Li, Federico Mensa, Jens Kort, Wei Liu AbbVie Inc., North Chicago, Illinois, United States EASL: ABT-493 + ABT-530 at EASL - (05/05/16)